- Investing Ideas
- U.S. Pharmaceuticals & Biotech Blue chip stocks
U.S. Pharmaceuticals & Biotech Blue chip stocks
Results
17
17 companies
Charles River Laboratories International
Market Cap: US$11.2b
Charles River Laboratories International, Inc.
CRL
US$233.41
7D
1.2%
1Y
46.4%
Axsome Therapeutics
Market Cap: US$12.0b
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
AXSM
US$233.80
7D
-4.3%
1Y
114.5%
Elanco Animal Health
Market Cap: US$12.4b
An animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide.
ELAN
US$24.82
7D
-0.7%
1Y
66.6%
ICON
Market Cap: US$12.8b
A clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally.
ICLR
US$167.72
7D
-3.1%
1Y
11.4%
Natera
Market Cap: US$38.7b
A diagnostics company, engages in the development and commercialization of molecular testing services worldwide.
NTRA
US$269.95
7D
-3.4%
1Y
68.3%
Insmed
Market Cap: US$25.1b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$115.61
7D
3.6%
1Y
17.8%
BioMarin Pharmaceutical
Market Cap: US$11.4b
A biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
BMRN
US$59.12
7D
0.2%
1Y
1.8%
Madrigal Pharmaceuticals
Market Cap: US$12.4b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$536.70
7D
1.6%
1Y
70.1%
Alnylam Pharmaceuticals
Market Cap: US$39.9b
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
ALNY
US$298.76
7D
-4.5%
1Y
-5.1%
Viatris
Market Cap: US$18.9b
Operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.
VTRS
US$16.27
7D
-2.6%
1Y
78.4%
Jazz Pharmaceuticals
Market Cap: US$15.3b
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.
JAZZ
US$243.82
7D
0.1%
1Y
121.1%
BeOne Medicines
Market Cap: US$33.2b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
ONC
US$298.70
7D
0.4%
1Y
19.3%
Royalty Pharma
Market Cap: US$32.5b
Operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
RPRX
US$56.43
7D
-2.3%
1Y
57.4%
Neurocrine Biosciences
Market Cap: US$17.8b
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
NBIX
US$177.11
7D
1.6%
1Y
32.7%
Merck
Market Cap: US$305.1b
Operates as a healthcare company worldwide.
MRK
US$123.54
7D
-4.6%
1Y
48.2%
Krystal Biotech
Market Cap: US$10.8b
A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
KRYS
US$365.81
7D
-2.5%
1Y
146.9%
Gilead Sciences
Market Cap: US$161.2b
A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
GILD
US$129.83
7D
-1.1%
1Y
18.4%